Coeptis Pharmaceuticals, Inc., a biopharmaceutical company, has entered into an agreement to acquire all outstanding shares of Elto Pharma, Inc. Elto is developing eltoprazine, a serotonergic agonist in Phase IIb development for the treatment of Parkinson’s disease levodopa-induced dyskinesias (Parkinson’s LID). Elto is a joint venture between Amarantus Bioscience Holdings, Inc. and Psychogenics, Inc. Financial terms were not disclosed. “Eltoprazine will be a key long-term g...